Novel Cancer Vaccine Prevents Melanoma From Returning in First for mRNA
- On Wednesday, Merck and Moderna reported their personalized mRNA vaccine, Intismeran, combined with Keytruda reduced melanoma recurrence compared with Keytruda alone, marking the first positive late-stage trial results for an mRNA cancer vaccine.
- The ongoing Phase III trial randomized 1,137 patients with high-risk stage IIB through IV melanoma to receive Keytruda plus up to nine vaccine doses or Keytruda alone, building on earlier mid-stage findings.
- Moderna tailors each vaccine to the individual patient by analyzing mutations within their tumor, a highly targeted design requiring up to nine doses to administer the Intismeran treatment effectively.
- Following the announcement, Moderna shares jumped 40% and Merck rose 2%, with the companies reporting no new safety concerns and that the treatment met primary and secondary trial endpoints.
- January data showed the combination reduced melanoma recurrence or death risk by 49% after five years; the companies plan to present new data at an upcoming medical conference and share results with regulators.
72 Articles
72 Articles
The group collaborates with Merck, which also jumped by more than 11%. The New York Stock Exchange opened up on Wednesday, supported by the decline of the...
The Economic Times
Times of IndiaModerna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial
Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings offer hope for future growth beyond COVID-19 vaccines. Discussions with regulators are expected within the next few months.
Positive results in an advanced melanoma study: a custom mRNA vaccine of Moderna, combined with Merck's Keytruda, reduces the risk of recurrence and the spread of skin cancer. The market bets that promising tests can open up strong investments and new prospects for cancer immunotherapy
The progress has been announced in a press release in which no concrete data are provided on improving survival. If confirmed, it would be a historic milestone
Medical Xpress
Merck, Moderna claim 'promising' skin cancer vaccine results in key trial
U.S. pharmaceutical firms Merck and Moderna announced encouraging results Wednesday from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval.
Coverage Details
Bias Distribution
- 40% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
